Posted by Michael Wonder on 30 Jun 2026
Satellos receives FDA fast track designation for SAT-3247 for the treatment of Duchenne muscular dystrophy
29 June 2026 - SAT-3247 has now received FDA fast track, orphan drug and rare paediatric disease designations for Duchenne muscular dystrophy.
Satellos Bioscience today announced that the US FDA has granted fast track designation to SAT-3247 for the treatment of Duchenne.
